RSNA-MICCAI Brain Tumor Segmentation (BraTS) Challenge 2021
Lists
Only you see this
Abstract
The Brain Tumor Segmentation (BraTS) 2021 challenge is the 10th anniversary of BraTS and this year is jointly<br> organized by RSNA and MICCAI. Compared to the previous BraTS instances, the RSNA MICCAI BraTS challenge<br> utilizes multi-institutional multi-parametric magnetic resonance imaging (mpMRI) scans from both pre-operative<br> and post-operative timepoints, i.e., including surgically imposed cavities (instead of only pre-operative scans), and<br> focuses only on glioblastoma (instead of all glioma). Glioblastoma, and diffuse astrocytic glioma with molecular features of glioblastoma (WHO Grade 4 astrocytoma),<br> are the most common and aggressive malignant primary tumor of the central nervous system in adults, with<br> extreme intrinsic heterogeneity in appearance, shape, and histology. Glioblastoma patients have very poor<br> prognosis, and the current standard of care comprises surgical resection followed by radiotherapy and<br> chemotherapy. MGMT (O[6]-methylguanine-DNA methyltransferase) is a DNA repair enzyme that the methylation<br> of its promoter in newly diagnosed glioblastoma has been identified as a favorable prognostic factor and a<br> predictor of chemotherapy response. Thus determination of MGMT promoter methylation status in newly<br> diagnosed glioblastoma can influence treatment decision making. In consistency with the previous BraTS instances, BraTS'21 focuses on (Task 1) the evaluation of state-of-the-art<br> methods for the segmentation of intrinsically heterogeneous brain glioblastoma sub-regions in mpMRI scans.<br> Furthemore, to pinpoint the clinical relevance of this segmentation task, BraTS’21 also focuses on (Task 2) the<br> evaluation of methods to predict the MGMT promoter methylation status at the pre-operative scans, via<br> integrative analyses of quantitative imaging phenomic features and machine learning algorithms.<br> Ground truth annotations of the tumor sub-regions are created and approved by expert neuroradiologists for<br> every subject included in the training, validation, and testing datasets to quantitatively evaluate the predicted<br> tumor segmentations of Task 1, whereas the quantitative evaluation of Task 2 is performed according to clinical<br> data. Participants are free to choose whether they want to focus only on one or both tasks.
BibTeX
@inproceedings{bakas2021rsna,
author = {Spyridon Bakas and Christopher Carr and Adam E. Flanders and Jayashree Kalpathy–Cramer and John Mongan and Bjoern Menze and Luciano M. Prevedello},
title = {{RSNA-MICCAI Brain Tumor Segmentation (BraTS) Challenge 2021}},
booktitle = {Zenodo},
year = {2021},
doi = {10.5281/zenodo.4575162},
}Loading related content...